Bookmark and Share
Mitoxantrone (CID 4212) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(495)
 
 
Inactive(453)
 
 
Inconclusive(103)
 
 
Unspecified(427)
 
 
Top Targets:
7TM GPCR Srx(35)
 
 
 
 
 
7TM GPCR Srsx(27)
 
 
 
 
p450(22)
 
 
 
 
 
ABCG EPDR(15)
 
 
ABC MTABC3 MD..(12)
 
 
BioAssay Types:
Literature(599)
 
 
 
 
 
Confirmatory(421)
 
 
 
 
 
Screening(234)
 
 
 
 
 
BioActivity Types:
IC50(334)
 
 
 
 
 
Potency(289)
 
 
 
 
 
EC50(12)
 
 
 
AC50(11)
 
 
 
Ki(2)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 1281    Data Row: 1478   Total Pages: 30   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103167833]
IC50 4e-05Cytotoxic potency required to inhibit L1210 cell growth by 50% after cell drug contact for 48 hrs [AID98563, Type: Literature]
View
2
[SID103167833]
GI50 0.00033Cytotoxicity against human HL60 cells after 48 hrs by MTT assay [AID320437, Type: Literature]
View
3
[SID103167833]
IC50 0.00035Antiproliferative activity against MDA435/LCC6 cells by ELISA [AID272492, Type: Literature]
View
4
[SID103167833]
IC50 0.00055Concentration required to inhibit A2780-cell growth by 50% [AID10003, Type: Literature]
View
5
[SID103167833]
IC50 0.00055Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs [AID10007, Type: Literature]
View
6
[SID103167833]
IC50 0.00059Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay [AID524790, Type: Literature]
View
7
[SID103167833]
IC50 0.00065Cytotoxic potency required to inhibit G-361 cell growth by 50% [AID72412, Type: Literature]
View
8
[SID103167833]
IC50 0.00075Cytotoxicity against human H460M cancer cell line was determined after 144 hr [AID248039, Type: Literature]
View
9
[SID103167833]
IC50 0.00081Compound was tested in vitro for cytotoxicity against HL60 human leukemia cell line (72 hr exposure to compound) [AID81308, Type: Literature]
View
10
[SID103167833]
IC50 0.00083Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay [AID524795, Type: Literature]
View
11
[SID103167833]
IC50 0.00085Cytotoxicity against human H460M cancer cell line was determined after 1 hr [AID253343, Type: Literature]
View
12
[SID103167833]
IC50 0.00093Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay [AID524791, Type: Literature]
View
13
[SID103167833]
IC50 0.001Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay [AID524793, Type: Literature]
View
14
[SID103167833]
IC50 0.001Tested for the cytotoxicity against the repair deficient xrs-6 chinese hamster ovary cell line [AID51931, Type: Literature]
View
15
[SID103167833]
IC50 0.00112Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay [AID524796, Type: Literature]
View
16
[SID103167833]
IC50 0.00141Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay [AID524794, Type: Literature]
View
17
[SID103167833]
IC50 0.00148Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay [AID524792, Type: Literature]
View
18
[SID103167833]
IC50 0.0016In vitro for its inhibitory activity against murine L1210 leukemia [AID132862, Type: Literature]
View
19
[SID103167833]
IC50 0.0016Tested in vitro against murine L1210 leukemia. [AID98403, Type: Literature]
View
20
[SID103167833]
IC50 0.002In vitro extracellular concentration required to reduce cell population to 50% against L1210 leukemia cells [AID101065, Type: Literature]
View
21
[SID103167833]
IC50 0.0025Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay [AID683860, Type: Literature]
View
22
[SID103167833]
IC50 0.0026Cytotoxicity against human K562 cells after 5 days by XTT assay [AID312292, Type: Literature]
View
23
[SID103167833]
IC50 0.00265Cytotoxic potency required to inhibit CH1 cell growth by 50% [AID47499, Type: Literature]
View
24
[SID103167833]
IC50 0.00265Concentration required to inhibit CH1-cell growth by 50% [AID47668, Type: Literature]
View
25
[SID103167833]
IC50 0.003In vitro cytotoxicity against uterine sarcoma MES-SA cells [AID255789, Type: Literature]
View
26
[SID103167833]
IC50 0.003Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs [AID270854, Type: Literature]
View
27
[SID103167833]
IC50 0.003Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay. [AID221330, Type: Literature]
View
28
[SID103167833]
IC50 0.0031Tested against A549 lung carcinoma in the sulforhodamine B assay. [AID8485, Type: Literature]
View
29
[SID103167833]
IC50 0.0031Activity against A549 cancer cell line. [AID8690, Type: Literature]
View
30
[SID103167833]
IC50 0.0033Cytotoxicity against human LoVo cancer cell line was determined after 144 hr [AID248024, Type: Literature]
View
31
[SID103167833]
IC50 0.0043Antiproliferative activity against P388 cells by ELISA [AID272494, Type: Literature]
View
32
[SID103167833]
IC50 0.005Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay [AID98203, Type: Literature]
View
33
[SID103167833]
IC50 0.005In vitro inhibition of tumor cell growth in the human mammary tumor MCF-7 system [AID102597, Type: Literature]
View
34
[SID103167833]
IC50 0.0053Compound was evaluated for cytotoxicity against SCOV-3 cell lines. [AID200757, Type: other]
View
35
[SID103167833]
IC50 0.0053Concentration required to inhibit SKOV-3-cell growth by 50% [AID202844, Type: Literature]
View
36
[SID103167833]
IC50 0.0053Cytotoxic potency required to inhibit SKOV-3 cell growth 50% [AID202961, Type: Literature]
View
37
[SID103167833]
IC50 0.0056In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line DU145 [AID55805, Type: Literature]
View
38
[SID103167833]
IC50 0.0058Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay [AID145432, Type: Literature]
View
39
[SID103167833]
IC50 0.0058Antitumor activity against human ovarian OVCAR-3 cell lines. [AID145436, Type: Literature]
View
40
[SID103167833]
IC50 0.0058Inhibitory activity against OVCAR-3 cell line [AID145445, Type: Literature]
View
41
[SID103167833]
IC50 0.0058Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr [AID248060, Type: Literature]
View
42
[SID103167833]
IC50 0.006Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay. [AID223628, Type: Literature]
View
43
[SID103167833]
IC50 0.00611In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780 [AID10019, Type: Literature]
View
44
[SID103167833]
IC50 0.0068Cytotoxicity against human MKN45 cancer cell line was determined after 1 hr [AID253344, Type: Literature]
View
45
[SID103167833]
IC50 0.007Cytotoxicity against human PC3 cancer cell line was determined after 144 hr [AID248010, Type: Literature]
View
46
[SID103167833]
ID50 0.007In vitro inhibitory activity against L1210 leukemia cell line [AID130603, Type: Literature]
View
47
[SID103167833]
IC50 0.00706Compound was tested in vitro for cytotoxicity against MDR cell line K562R (72 hr exposure to compound) [AID95160, Type: Literature]
View
48
[SID103167833]
IC50 0.0071In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line PC3 [AID156652, Type: Literature]
View
49
[SID103167833]
IC50 0.008Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). [AID216435, Type: Literature]
View
50
[SID103167833]
IC50 0.0081Tested against WiDr colon (sensitive) in the sulforhodamine B assay. [AID216575, Type: Literature]
View